K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $10.11 (+0.20% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KTWO ranks #200 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and PDEX (Pro-Dex Inc.) posts a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $317.0K in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 96% of 52W Range • RSI-14 at 49 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 56/100 (D+) score, KTWO faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.09) or 200D SMA ($9.99) invalidates the momentum regime and cuts Target Base ($10.02) toward Bear Floor ($7.82).
K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) advanced +0.20% to $10.11, trading at 96% of its 52-week range ($9.84 – $10.12). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Vancouver, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) ("Deep Sea Minerals" or the "Company"), a seabed mineral exploration and development company f
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corporation (the "Company") today announced the pricing of its upsized initial public offering of 12,000,000 units at $10.00 per unit, with each unit con
<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxQSEtJbnQ1XzdQOVRtVTFoQmlQdzBqZ3BMNjNoem5TdWpMVkctQWxjdUJ2SnRkd0RnSDQwMFdSSncwZEdnbVFyRlF3T3o1TEM2N3ZoVGdsdE1VNU8xTTVvb2xlNXNJOE1tVHlzUDYzVW82MUhXeWpsTk03LUF
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE9iaVRLdVd6QWF6RlFKZ2IwVmluMjFKRmJqamZWc1RTYVlvUFRSd0NhUk9HMjNYS1pxdS05QjZCYWd1Y2lCTzdqQUR0Q2ttRlVtSXNuQ1BFcXFGSVlqMGFsTnFXekc?oc=5" target="_blank">K2 Cap
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KTWO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KTWO. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) ranks #200 by composite RQD confidence (56/100, grade D+) and #571 by equity capitalization ($202.2M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with KTWO at 56/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KTWO
ACTIVE
K2 Capital Acquisition Corporation Class A Ordinary Share | D+ | 56/100 | — | — | — | +0.20% | $202.2M | Benchmark Subject |
| UTMD Utah Medical Products Inc. | C | 62/100 | — | 57.1% | 26.9% | +3.64% | $216.7M | /utmd-vs-ktwo → |
| PDEX Pro-Dex Inc. | D+ | 54/100 | 22.2x | 29.3% | 23.2% | -0.88% | $186.1M | /pdex-vs-ktwo → |
| STIM Neuronetics Inc. | E | 28/100 | — | 48.5% | -35.0% | -8.44% | $171.4M | /stim-vs-ktwo → |
| PROF Profound Medical Corp. | D- | 40/100 | — | 70.8% | -35.0% | +2.44% | $240.0M | /prof-vs-ktwo → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported GAAP revenue of $317.0K , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KTWO closed FY2025 with $754.7K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $317.0K | $0 | — | — | $754.7K | — |
As of 2026-11-03, K2 Capital Acquisition Corporation Class A Ordinary Share (NASDAQ: KTWO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $10.11 (+0.20% 1D, market cap $202.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KTWO ranks #200 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), KTWO carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, UTMD (Utah Medical Products Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 26.9%, cap $216.7M) and PDEX (Pro-Dex Inc.) posts a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
Per KTWO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002086524), K2 Capital Acquisition Corporation Class A Ordinary Share generated $317.0K in revenue, $0 in net income, and $0 in free cash flow against $754.7K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
KTWO last traded at $10.11 (+0.20% on volume of 528 shares), positioning the stock +0.20% above its 50-day simple moving average ($10.09) and +1.20% above its 200-day simple moving average ($9.99). Across its 52-week range of $9.84 to $10.12, KTWO sits at the 96.4% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±1.8% ($9.93 to $10.29).
K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $10.11 (+0.20% 1D, market capitalization $202.2M).
. Per the market data, gross, operating, and net margins are each reported as 0%, and the financials section reports FY 2025 revenue as —.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) reported $317.0K in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $754.7K in total assets against $0 in total debt.
Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or 2nd-order bottlenecks are identified in the source data.
Real-time company headlines, analyst actions, and sector developments for K2 Capital Acquisition Corporation Class A Ordinary Share (KTWO) • Click "Debate This Headline" to argue it in the Roar Pit below
Vancouver, British Columbia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) ("Deep Sea Minerals" or the "Company"), a seabed mineral exploration and development company f
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corporation (the "Company") today announced the pricing of its upsized initial public offering of 12,000,000 units at $10.00 per unit, with each unit con
<a href="https://news.google.com/rss/articles/CBMigAJBVV95cUxQSEtJbnQ1XzdQOVRtVTFoQmlQdzBqZ3BMNjNoem5TdWpMVkctQWxjdUJ2SnRkd0RnSDQwMFdSSncwZEdnbVFyRlF3T3o1TEM2N3ZoVGdsdE1VNU8xTTVvb2xlNXNJOE1tVHlzUDYzVW82MUhXeWpsTk03LUF
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE9iaVRLdVd6QWF6RlFKZ2IwVmluMjFKRmJqamZWc1RTYVlvUFRSd0NhUk9HMjNYS1pxdS05QjZCYWd1Y2lCTzdqQUR0Q2ttRlVtSXNuQ1BFcXFGSVlqMGFsTnFXekc?oc=5" target="_blank">K2 Cap
Don't sleep on KTWO's setup in Health Care. Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 13 of 20 on an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.
@SiliconVal_Bull Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.09 and keeping dry powder in case we test $9.38.
Fading this rally in KTWO at $10.09. Per the Roarable RQD rating, the Fundamental Cash Engine pillar scores 10 of 20 with ROIC at 0% and FCF yield at 0%, and the SEC financials report $0.0M revenue.. With a beta of 1.0 and the stock sitting at $10.09 (52-wk range $9.84–$10.12), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).